Fig. 8

Comparison between IL-2C therapy and high-dose IL-2 therapy. IL-2C treatment induces more expansion of splenic immune cells than high-dose IL-2 therapy (a-e). a Both IL-2C (P = 0.004) and high-dose IL-2 (P = 0.008) increased the number of splenocytes; however, the effect of IL-2C was greater than that of high-dose IL-2 (P = 0.019). b CD8⁺ T cells were also increased more by IL-2C than high-dose IL-2 (P = 0.006). c Only IL-2C increased the number of NK cells (P = 0.002). d-e IL-2C increased both ratio of CD8⁺CD44⁺ T cells/Tregs (P = 0.002, d), and ratio of CD49b⁺ NK cells/Tregs (P = 0.001, e), whereas high-dose IL-2 did not. f Either IL-2C or high-dose IL-2 did not suppress growth of RCC significantly. Tumor weight on day 28 did not differ significantly between the IL-2C and the high-dose IL-2 groups (P = 0.353). g Pulmonary edema looked more severe in the high-dose IL-2 group than IL-2 complex group; however difference was not significant. Images are shown at 200× magnification. IL-2C, interleukin-2/anti-interleukin-2 antibody complex; HD, high dose; Treg, regulatory T cell